Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status

Urology

Volumn 63, Issue 2, 2004, Pages 392-397

  Maas, Simone ^c   Warskulat, Ulrich ^c   Steinhoff, Christine ^c   Mueller, Wolfram ^a   Grimm, Marc Oliver ^c   Schulz, Wolfgang A ^b   Seifert, Hans Helge ^c  

^a Gemeinschaftspraxis Pathologie   (Germany)

^b Urologisches Forschungslabor   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOACCUMULATION; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; DOWN REGULATION; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

EID: 1242318839     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.08.023     Document Type: Article

References (25)

1. Green D.R., Evan G.I. A matter of life and death. Cancer Cell. 1:2002;19-30.
2. Owen-Schaub L.B. Fas function and tumour progression use it and lose it . Cancer Cell. 1:2002;95-96.
3. Igney F.H., Krammer P.H. Death and anti-death tumour resistance to apoptosis . Nat Rev. 2:2002;277-288.
4. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis a link between cancer genetics and chemotherapy . Cell. 108:2002;153-164.
5. Owen-Schaub L.B., Chan H., Cusack J.C., et al. Fas and Fas ligand interaction in malignant disease. Int J Oncol. 17:2000;5-12.
6. Santourlidis S., Warskulat U., Florl A.R., et al. Hypermethylation of the tumour necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo1) gene promoter at rel/nuclear κB sites in prostatic carcinoma. Mol Carcinogenesis. 32:2001;36-43.
7. Ivanov V.N., Bhoumik A., Krasilnikov M., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell. 7:2001;517-528.
8. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
9. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
10. Maecker H.L., Yun Z., Maecker H.T., et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell. 2:2002;139-148.
11. Ørntoft T.F., Wolf H. Molecular alterations in bladder cancer. Urol Res. 26:1998;223-233.
12. Lee S.H., Shin S.M., Park W.S., et al. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:1999;3068-3072.
13. Hermanek P, and Sobin LH (Eds), for the International Union Against Cancer: TNM Classifications of Malignant Tumours, 4th ed, 2nd revision. Berlin, Springer-Verlag, 1992.
14. Steinhoff C., Prior A., Reichmann G., et al. Activity of E2F-dependent promotors in bladder carcinoma cells and their use for tumour-specific targeting of p53-induced apoptosis. Int J Oncol. 21:2002;1033-1040.
15. Steinhoff C: PhD thesis, Heinrich Heine University, Düsseldorf, Germany, 2001. http://www.ulb.uni-duesseldorf.de/diss/mathnat/2001/steinhoff. html.
16. Clasen S., Schulz W.A., Gerharz C.D., et al. Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 77:1998;515-521.
17. Grimm M.O., Jurgens B., Schulz W.A., et al. Inactivation of tumour suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res. 23:1995;293-300.
18. Scriven S.D., Booth C., Thomas D.F.M., et al. Reconstitution of human urothelium from monolayer cultures. J Urol. 158:1997;1147-1152.
19. Lee S.H., Lee W.S., Park S.Y., et al. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. Br J Urol. 83:1999;698-702.
20. Giannopoulou I., Nakopoulou L., Zervas A., et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer prognostic implications . Urol Res. 30:2002;342-345.
21. Mizutani Y., Yoshida O., Boavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol. 160:1998;571-576.
22. Mizutani Y., Hongo F., Sato N., et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 92:2001;287-293.
23. Perabo F.G., Mattes R.H., Wirger A., et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. Urol Oncol. 6:2001;163-169.
24. Perabo F.G., Kamp S., Schmidt D., et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer. 84:2001;1330-1338.
25. Mizutani Y., Yoshida O. Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells. J Infect Chemother. 5:1999;139-143.